2nw4
From Proteopedia
(New page: 200px<br /><applet load="2nw4" size="450" color="white" frame="true" align="right" spinBox="true" caption="2nw4, resolution 3.00Å" /> '''Crystal Structure of...) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:2nw4.gif|left|200px]]<br /><applet load="2nw4" size=" | + | [[Image:2nw4.gif|left|200px]]<br /><applet load="2nw4" size="350" color="white" frame="true" align="right" spinBox="true" |
caption="2nw4, resolution 3.00Å" /> | caption="2nw4, resolution 3.00Å" /> | ||
'''Crystal Structure of the Rat Androgen Receptor Ligand Binding Domain Complex with BMS-564929'''<br /> | '''Crystal Structure of the Rat Androgen Receptor Ligand Binding Domain Complex with BMS-564929'''<br /> | ||
==Overview== | ==Overview== | ||
| - | A novel, highly potent, orally active, nonsteroidal tissue selective | + | A novel, highly potent, orally active, nonsteroidal tissue selective androgen receptor (AR) modulator (BMS-564929) has been identified, and this compound has been advanced to clinical trials for the treatment of age-related functional decline. BMS-564929 is a subnanomolar AR agonist in vitro, is highly selective for the AR vs. other steroid hormone receptors, and exhibits no significant interactions with SHBG or aromatase. Dose response studies in castrated male rats show that BMS-564929 is substantially more potent than testosterone (T) in stimulating the growth of the levator ani muscle, and unlike T, highly selective for muscle vs. prostate. Key differences in the binding interactions of BMS-564929 with the AR relative to the native hormones were revealed through x-ray crystallography, including several unique contacts located in specific helices of the ligand binding domain important for coregulatory protein recruitment. Results from additional pharmacological studies effectively exclude alternative mechanistic contributions to the observed tissue selectivity of this unique, orally active androgen. Because concerns regarding the potential hyperstimulatory effects on prostate and an inconvenient route of administration are major drawbacks that limit the clinical use of T, the potent oral activity and tissue selectivity exhibited by BMS-564929 are expected to yield a clinical profile that provides the demonstrated beneficial effects of T in muscle and other tissues with a more favorable safety window. |
==About this Structure== | ==About this Structure== | ||
| - | 2NW4 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Rattus_norvegicus Rattus norvegicus] with 8NH as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http:// | + | 2NW4 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Rattus_norvegicus Rattus norvegicus] with <scene name='pdbligand=8NH:'>8NH</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2NW4 OCA]. |
==Reference== | ==Reference== | ||
| Line 14: | Line 14: | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: An, Y.]] | [[Category: An, Y.]] | ||
| - | [[Category: Beehler, B | + | [[Category: Beehler, B C.]] |
[[Category: Bi, Y.]] | [[Category: Bi, Y.]] | ||
[[Category: Fura, A.]] | [[Category: Fura, A.]] | ||
[[Category: Golla, R.]] | [[Category: Golla, R.]] | ||
| - | [[Category: Grover, G | + | [[Category: Grover, G J.]] |
| - | [[Category: Hamann, L | + | [[Category: Hamann, L G.]] |
| - | [[Category: Kish, K | + | [[Category: Kish, K F.]] |
| - | [[Category: Krystek, S | + | [[Category: Krystek, S R.]] |
| - | [[Category: Kuhns, J | + | [[Category: Kuhns, J E.]] |
| - | [[Category: Lupisella, J | + | [[Category: Lupisella, J A.]] |
| - | [[Category: Manfredi, M | + | [[Category: Manfredi, M C.]] |
| - | [[Category: Mookhtiar, K | + | [[Category: Mookhtiar, K A.]] |
[[Category: Ostrowski, J.]] | [[Category: Ostrowski, J.]] | ||
| - | [[Category: Sack, J | + | [[Category: Sack, J S.]] |
[[Category: Seethala, R.]] | [[Category: Seethala, R.]] | ||
| - | [[Category: Sleph, P | + | [[Category: Sleph, P G.]] |
[[Category: Sun, C.]] | [[Category: Sun, C.]] | ||
[[Category: 8NH]] | [[Category: 8NH]] | ||
| Line 38: | Line 38: | ||
[[Category: transcription regulation]] | [[Category: transcription regulation]] | ||
| - | ''Page seeded by [http:// | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:11:40 2008'' |
Revision as of 16:11, 21 February 2008
|
Crystal Structure of the Rat Androgen Receptor Ligand Binding Domain Complex with BMS-564929
Overview
A novel, highly potent, orally active, nonsteroidal tissue selective androgen receptor (AR) modulator (BMS-564929) has been identified, and this compound has been advanced to clinical trials for the treatment of age-related functional decline. BMS-564929 is a subnanomolar AR agonist in vitro, is highly selective for the AR vs. other steroid hormone receptors, and exhibits no significant interactions with SHBG or aromatase. Dose response studies in castrated male rats show that BMS-564929 is substantially more potent than testosterone (T) in stimulating the growth of the levator ani muscle, and unlike T, highly selective for muscle vs. prostate. Key differences in the binding interactions of BMS-564929 with the AR relative to the native hormones were revealed through x-ray crystallography, including several unique contacts located in specific helices of the ligand binding domain important for coregulatory protein recruitment. Results from additional pharmacological studies effectively exclude alternative mechanistic contributions to the observed tissue selectivity of this unique, orally active androgen. Because concerns regarding the potential hyperstimulatory effects on prostate and an inconvenient route of administration are major drawbacks that limit the clinical use of T, the potent oral activity and tissue selectivity exhibited by BMS-564929 are expected to yield a clinical profile that provides the demonstrated beneficial effects of T in muscle and other tissues with a more favorable safety window.
About this Structure
2NW4 is a Single protein structure of sequence from Rattus norvegicus with as ligand. Full crystallographic information is available from OCA.
Reference
Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats., Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR Jr, Bi Y, Sun C, Seethala R, Golla R, Sleph PG, Fura A, An Y, Kish KF, Sack JS, Mookhtiar KA, Grover GJ, Hamann LG, Endocrinology. 2007 Jan;148(1):4-12. Epub 2006 Sep 28. PMID:17008401
Page seeded by OCA on Thu Feb 21 18:11:40 2008
Categories: Rattus norvegicus | Single protein | An, Y. | Beehler, B C. | Bi, Y. | Fura, A. | Golla, R. | Grover, G J. | Hamann, L G. | Kish, K F. | Krystek, S R. | Kuhns, J E. | Lupisella, J A. | Manfredi, M C. | Mookhtiar, K A. | Ostrowski, J. | Sack, J S. | Seethala, R. | Sleph, P G. | Sun, C. | 8NH | Androgen receptor | Ligand-binding domain | Nuclear receptor | Steroid receptor | Transcription regulation
